B Kuipers
Overview
Explore the profile of B Kuipers including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
398
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
van den Broek B, van Els C, Kuipers B, van Aerde K, Henriet S, de Groot R, et al.
Clin Exp Immunol
. 2019 Sep;
198(3):381-389.
PMID: 31487400
Vaccination against meningococcal serogroup B is recommended for patients with a complement deficiency; however, although immunogenicity in this patient group has been shown, efficacy has not yet been established. In...
2.
Gill C, Kuipers B, Simpson C, Lai V, Reimer K, Cullen W
Environ Sci Technol
. 2011 Jun;
31(8):343A.
PMID: 21650404
No abstract available.
3.
Kuipers B, van den Dobbelsteen G, Wedege E, van Alphen L
Methods Mol Med
. 2011 Feb;
67:131-45.
PMID: 21337142
Immunoassays employ a range of methods to detect and quantify antigens or antibodies and to study the composition of antigens. This chapter describes four useful immunoassays for serological characterization of...
4.
Berrington A, Tan Y, Srikhanta Y, Kuipers B, van der Ley P, Peak I, et al.
FEMS Immunol Med Microbiol
. 2002 Nov;
34(4):267-75.
PMID: 12443826
Neisseria meningitidis expresses a range of lipooligosaccharide (LOS) structures, comprising of at least 13 immunotypes (ITs). Meningococcal LOS is subject to phase variation of its terminal structures allowing switching between...
5.
de Kleijn E, van Eijndhoven L, Vermont C, Kuipers B, van Dijken H, Rumke H, et al.
Vaccine
. 2001 Oct;
20(3-4):352-8.
PMID: 11672897
A clinical phase II trial with the RIVM hexavalent OMV vaccine containing six different PorAs was carried out in toddlers (2-3 years) and schoolchildren (7-8 years) in The Netherlands. Children...
6.
Toropainen M, Saarinen L, van der Ley P, Kuipers B, Kayhty H
Microb Pathog
. 2001 Mar;
30(3):139-48.
PMID: 11273739
The major outer membrane protein PorA of Neisseria meningitidis is the target for bactericidal serosubtyping antibodies and is currently considered as a potential vaccine candidate against group B meningococcal disease....
7.
Jansen C, Kuipers B, van der Biezen J, de Cock H, van der Ley P, Tommassen J
FEMS Immunol Med Microbiol
. 2000 Feb;
27(3):227-33.
PMID: 10683467
In vitro folded and the denatured form of PorA P1.6 from Neisseria meningitidis strain M990 were used for immunization studies in mice. Previously, the antigen was isolated from cytoplasmic inclusion...
8.
de Kleijn E, de Groot R, Labadie J, Lafeber A, van den Dobbelsteen G, van Alphen L, et al.
Vaccine
. 2000 Jan;
18(15):1456-66.
PMID: 10618543
To study the reactogenicity and immunogenicity of a hexavalent meningococcal outer-membrane-vesicle vaccine (OMV), two different dosages of this vaccine (7.5 and 15 microg of individual PorA proteins) consisting of vesicles...
9.
Steeghs L, Kuipers B, Hamstra H, Kersten G, van Alphen L, van der Ley P
Infect Immun
. 1999 Sep;
67(10):4988-93.
PMID: 10496868
The immunogenicity of outer membrane complexes (OMCs) or heat-inactivated bacteria of a lipopolysaccharide (LPS)-deficient mutant derived from meningococcal strain H44/76 was studied. The immune response in BALB/c mice to the...
10.
Levi M, van der Poll T, ten Cate H, Kuipers B, Biemond B, Jansen H, et al.
Am J Respir Crit Care Med
. 1998 Jul;
158(1):92-8.
PMID: 9655712
Activation and inhibition of coagulation and fibrinolysis was analyzed in bronchoalveolar lavage (BAL) fluids obtained from endotoxin-challenged chimpanzees. The mediatory role of tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6) on...